Comparison of the safety and efficacy of a recombinant feline leukemia virus (FeLV) vaccine delivered transdermally and an inactivated FeLV vaccine delivered subcutaneously

• Published in: Veterinary therapeutics Vol. 5; no. 4; pp. 258 - 262
• Main Authors: Grosenbaugh, D.A, Leard, T, Pardo, M.C, Motes-Kreimeyer, L, Royston, M
• Format: Journal Article
• Language: English
• Published: United States 2004
• Subjects: Administration, Cutaneous; Animals; Antigens, Viral - blood; Cats; drug delivery systems; Feline leukemia virus; inactivated vaccines; Injections, Subcutaneous - veterinary; Leukemia Virus, Feline - immunology; Leukemia, Feline - prevention & control; Random Allocation; recombinant vaccines; Retroviridae Proteins, Oncogenic - administration & dosage; Retroviridae Proteins, Oncogenic - standards; Safety; Specific Pathogen-Free Organisms; Treatment Outcome; Vaccination - veterinary; Vaccines, Inactivated - administration & dosage; Vaccines, Inactivated - standards; Vaccines, Synthetic - administration & dosage; Vaccines, Synthetic - standards; Viral Vaccines - administration & dosage; Viral Vaccines - standards

The efficacy of a new recombinant FeLV vaccine (rFeLV), delivered transdermally via a needle-free delivery device was compared to that of an inactivated FeLV vaccine (FeLV-k), administered subcutaneously, with a conventional needle and syringe. Kittens were immunized with either rFeLV (0.25 ml, tran...